Renaissance Technologies’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Renaissance Technologies’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-282,877	Closed	-$77K	–	4561
2022 Q3	$77K	Sell	282,877 -136,922	-33%	-$54.2K	﹤0.01%	3664
2022 Q2	$147K	Sell	419,799 -39,400	-9%	-$19.9K	﹤0.01%	3750
2022 Q1	$312K	Buy	+459,199	New	+$504K	﹤0.01%	3457
2021 Q4	–	Sell	-47,200	Closed	-$216K	–	4336
2021 Q3	$216K	Sell	47,200 -49,300	-51%	-$217K	﹤0.01%	3179
2021 Q2	$428K	Buy	+96,500	New	+$491K	﹤0.01%	3022

Renaissance Technologies's LOGC Position: Q4 2022 in Review

Renaissance Technologies sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 282,877 shares — an estimated $77K sold.

Renaissance Technologies first reported a position in LOGC in Q2 2021 and held it in 5 quarters. The position peaked at $428K in Q2 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Renaissance Technologies reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Renaissance Technologies sold 282,877 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $77K.
Renaissance Technologies first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Renaissance Technologies's LogicBio Therapeutics, Inc. Common Stock position peaked at $428K in Q2 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.